Last reviewed · How we verify
NCT05669638
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
trial in Immunotherapy in 80 participants. Status unknown.
1 May 2025
Quick facts
| Lead sponsor | Xuanwu Hospital, Beijing |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 May 2023 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2025 |
| Sites | 1 location across China |
Conditions studied
- Immunotherapy — all drugs for Immunotherapy →
- ADR — all drugs for ADR →
Sponsor
Xuanwu Hospital, Beijing
Who can join
18 and older, any sex, with Immunotherapy or ADR. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about in the development process of adverse reactions of anti-PD1 immunotherapy. The main question it aims to observe: * The autoantibody profile of patients * The adverse reactions of patients * The changes of immune cells and cytokine in patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Functional roles and clinical potential of SOX1 in cancer as a biomarker and therapeutic target.
Zhou X, Wang J, Yang F, Gao Y, et al · · 2026 · PMID 41931180 · DOI 10.1007/s12672-026-04431-4
Verify or expand the search:
- PubMed search for NCT05669638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Immunotherapy
Currently open trials in the same condition.
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
- NCT07436845 — Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arte · recruiting
- NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting
Other Xuanwu Hospital, Beijing trials
Trials by the same sponsor.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07519044 — Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel Occlusion · Phase 4 · not yet recruiting
- NCT07396077 — Pre-operative Risk Assessment Combined With Targeted Intervention in the Chinese Elderly With Spine Surgery II · NA · not yet recruiting
- NCT07457125 — The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT07479446 — Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05669638 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuanwu Hospital, Beijing
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05669638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing